{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:54:28Z","timestamp":1783090468738,"version":"3.54.6"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of levodopa\u2010induced dyskinesia in Parkinson's disease (PD) is a largely unmet need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa\u2010induced dyskinesia. This was a phase 2b study dose finding study to investigate efficacy and safety of 2.5\u2009mg, 5\u2009mg and 7,5\u2009mg b.i.d. in a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PD patients with \u22652\u2009hours of troublesome dyskinesia were randomized to placebo or mesdopetam twice daily for 12\u2009weeks. The primary efficacy endpoint was change from baseline to week 12 in ON time without troublesome dyskinesia (Good ON\u2010time) as recorded with home diaries. Secondary efficacy endpoints assessing ON phase dyskinesia were the modified UDysRS (sum of parts 1, 3 and 4) and MDS\u2010UPDRS part 4.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Groups did not differ in change from baseline to end of study in Good ON\u2010time. Several secondary assessments for ON phase dyskinesia such as the modified UDysRS showed clinically relevant and statistically significant improvements for the 2.5 and 7.5\u2009mg doses. OFF time showed dose dependent decrease with highest efficacy for the 7.5\u2009mg dose. The adverse event profile was similar to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study mesdopetam failed to increase Good ON\u2010time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5\u2009mg b.i.d. to be the preferred dose for further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70004","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T18:51:56Z","timestamp":1741719116000},"page":"796-806","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial"],"prefix":"10.1002","volume":"12","author":[{"given":"Angelo","family":"Antonini","sequence":"first","affiliation":[{"name":"Department of Neuroscience University of Padua  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-4791","authenticated-orcid":false,"given":"Padraig","family":"O'Suilleabhain","sequence":"additional","affiliation":[{"name":"Department of Neurology and Peter O'Donnell Jr. Brain Institute University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-0033","authenticated-orcid":false,"given":"Fabricio","family":"Stocchi","sequence":"additional","affiliation":[{"name":"University San Raffaele Rome and Institute for Research and Medical Care (IRCCS) San Raffaele  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Landstr\u00f6m","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories Sweden AB (IRLAB)  G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-880X","authenticated-orcid":false,"given":"Susanna","family":"Waters","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories Sweden AB (IRLAB)  G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clas","family":"Sonesson","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories Sweden AB (IRLAB)  G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Tedroff","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories Sweden AB (IRLAB)  G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"e_1_2_10_4_1","volume-title":"Behavioral and Electrophysiological Characterization of the Antidyskinetic Treatments in a Rodent Model of PD\u2010LID. Society for Neuroscience","author":"Ronaghi A","year":"2022"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264226"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1401991"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00334"},{"issue":"1","key":"e_1_2_10_8_1","first-page":"435","article-title":"Dopamine D3 receptor modulates l\u2010DOPA\u2010induced dyskinesia by targeting D1 receptor\u2010mediated striatal signaling","volume":"27","author":"Solis O","year":"2017","journal-title":"Cereb Cortex"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.792"},{"key":"e_1_2_10_10_1","unstructured":"CarrollC OdinP SonessonC et al.A Phase 2a study evaluating mesdopetam for the treatment of levodopa\u2010induced dyskinesia in Parkinson's disease. NCT03368170 (manuscript in preparation)."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0071-3"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22341"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.846126"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00331-w"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70004","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:19:08Z","timestamp":1779085148000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/mdc3.70004"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70004","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"2024-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}